RNS Number : 8433D
GSK PLC
11 September 2024
 

Issued: 11 September 2024, London UK

 

Statement: Zantac (ranitidine) litigation - Dixon case

 

 


GSK plc (LSE/NYSE: GSK) today confirmed it has reached a confidential settlement with Mr. Isaac Dixon, resolving the prostate cancer case filed in Illinois State Court. GSK does not admit any liability in this settlement. The case will now be dismissed.

 

Since 2019, following the 16 epidemiological studies looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.

 

GSK will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.

 

​

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

 

GSK enquiries




Media:

Tim Foley

+44 (0) 20 8047 5502

(London)


Dan Smith

+44 (0) 20 8047 5502

(London)


Kathleen Quinn

+1 202 603 5003

(Washington DC)


Lyndsay Meyer

+1 202 302 4595

(Washington DC)





Investor Relations:

Nick Stone

+44 (0) 7717 618834

(London)


James Dodwell

+44 (0) 20 8047 2406

(London)


Mick Readey

+44 (0) 7990 339653

(London)


Josh Williams

+44 (0) 7385 415719

(London)


Camilla Campbell

+44 (0) 7803 050238

(London)


Steph Mountifield

+44 (0) 7796 707505

(London)


Jeff McLaughlin

+1 215 751 7002

(Philadelphia)


Frannie DeFranco

+1 215 751 4855

(Philadelphia)





 

Cautionary statement regarding forward-looking statements
 GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and GSK's Q2 Results for 2024.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STREAKNFFASLEFA
Gsk (LSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Gsk Charts.